SynthesisAIDS research and therapy2023

An indirect comparison of 144-week efficacy, safety, and tolerability of dolutegravir plus lamivudine and second-generation integrase inhibitor-based, 3-drug, single-tablet regimens in therapy-naive people with HIV-1.

Lee A Evitt et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.